Although response is higher in TNBC than in hormone receptor positive (HR+) and HER2+ breast cancers, the efficacy of ICI monotherapy, while correlated with tumor and/or immune cell PD-L1 positivity, remains low. This evidence concerns the gene ERBB2 and breast carcinoma.